{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+once+daily&page=14",
    "query": {
      "intervention": "Placebo once daily",
      "page": 14
    },
    "page_size": 10
  },
  "pagination": {
    "page": 14,
    "page_size": 10,
    "total_count": 5496,
    "total_pages": 550,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+once+daily&page=15&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+once+daily&page=13&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-15T03:45:43.835Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00622700",
      "title": "Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "Teriflunomide",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 618,
      "start_date": "2008-02",
      "completion_date": "2016-02",
      "has_results": true,
      "last_update_posted_date": "2017-03-13",
      "last_synced_at": "2026-10-15T03:45:43.835Z",
      "location_count": 19,
      "location_summary": "Cullman, Alabama • Phoenix, Arizona • Fort Collins, Colorado + 15 more",
      "locations": [
        {
          "city": "Cullman",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Fort Collins",
          "state": "Colorado"
        },
        {
          "city": "Maitland",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00622700"
    },
    {
      "nct_id": "NCT01802866",
      "title": "Safety and Efficacy Assessment Treatment Trials of Emixustat Hydrochloride",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Geographic Atrophy"
      ],
      "interventions": [
        {
          "name": "ACU-4429",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Kubota Vision Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "55 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "55 Years and older"
      },
      "enrollment_count": 508,
      "start_date": "2013-02",
      "completion_date": "2016-05",
      "has_results": false,
      "last_update_posted_date": "2017-07-02",
      "last_synced_at": "2026-10-15T03:45:43.835Z",
      "location_count": 1,
      "location_summary": "Phoenix, Arizona",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01802866"
    },
    {
      "nct_id": "NCT07660731",
      "title": "A Study to Learn How Different Amounts of the Study Medicine Called PF-08103402 Are Tolerated and Act in the Body in Healthy Adults or Adults With Mild To-moderate Asthma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteer Study",
        "Healthy Adults",
        "Healthy Participants",
        "Asthma"
      ],
      "interventions": [
        {
          "name": "PF-08103402",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Midazolam",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 133,
      "start_date": "2026-06-17",
      "completion_date": "2027-03-30",
      "has_results": false,
      "last_update_posted_date": "2026-10-13",
      "last_synced_at": "2026-10-15T03:45:43.835Z",
      "location_count": 1,
      "location_summary": "New Haven, Connecticut",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07660731"
    },
    {
      "nct_id": "NCT00904202",
      "title": "A Study Of Lidocaine Patch 5% Alone, Gabapentin Alone, And Lidocaine Patch 5% And Gabapentin In Combination For The Relief Of Pain In Patients With Diverse Peripheral Neuropathic Pain Conditions",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Postherpetic Neuralgia",
        "Diabetic Neuropathy",
        "Complex Regional Pain Syndrome",
        "Carpal Tunnel Syndrome",
        "HIV Neuropathy",
        "Idiopathic Sensory Neuropathy",
        "Peripheral Neuropathy"
      ],
      "interventions": [
        {
          "name": "Placebo Capsules + Placebo Patch",
          "type": "DRUG"
        },
        {
          "name": "Placebo capsules + Lidoderm®",
          "type": "DRUG"
        },
        {
          "name": "Gabapentin + Placebo",
          "type": "DRUG"
        },
        {
          "name": "Gabapentin + Lidoderm®",
          "type": "DRUG"
        },
        {
          "name": "Gabapentin 300 mg capsules 1800 mg/day + placebo patch",
          "type": "DRUG"
        },
        {
          "name": "Gabapentin 1800 mg/day + Lidoderm patch",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Endo USA Inc., a Keenova Therapeutics Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 62,
      "start_date": "2003-01",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2024-01-02",
      "last_synced_at": "2026-10-15T03:45:43.835Z",
      "location_count": 7,
      "location_summary": "Birmingham, Alabama • Hueytown, Alabama • Phoenix, Arizona + 4 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Hueytown",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Pembroke Pines",
          "state": "Florida"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00904202"
    },
    {
      "nct_id": "NCT00691405",
      "title": "A Dose Ranging Study of Arformoterol Given Once Daily Compared to Arformoterol Given Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "COPD"
      ],
      "interventions": [
        {
          "name": "Arformoterol tartrate inhalation solution",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sumitomo Pharma America, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "35 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "35 Years and older"
      },
      "enrollment_count": 215,
      "start_date": "2003-10",
      "completion_date": "2004-05",
      "has_results": false,
      "last_update_posted_date": "2012-02-22",
      "last_synced_at": "2026-10-15T03:45:43.835Z",
      "location_count": 31,
      "location_summary": "Encinitas, California • Long Beach, California • Brandon, Florida + 28 more",
      "locations": [
        {
          "city": "Encinitas",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Brandon",
          "state": "Florida"
        },
        {
          "city": "Cleawater",
          "state": "Florida"
        },
        {
          "city": "Fort Lauderdale",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00691405"
    },
    {
      "nct_id": "NCT03078322",
      "title": "AV-101 as Adjunct Antidepressant Therapy in Patients With Major Depression",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Major Depressive Disorder"
      ],
      "interventions": [
        {
          "name": "AV-101",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "VistaGen Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 180,
      "start_date": "2018-03-05",
      "completion_date": "2019-10-01",
      "has_results": false,
      "last_update_posted_date": "2019-10-09",
      "last_synced_at": "2026-10-15T03:45:43.835Z",
      "location_count": 22,
      "location_summary": "Garden Grove, California • Los Angeles, California • National City, California + 18 more",
      "locations": [
        {
          "city": "Garden Grove",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "National City",
          "state": "California"
        },
        {
          "city": "Oakland",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03078322"
    },
    {
      "nct_id": "NCT00811395",
      "title": "Long Term Safety of Teriflunomide When Added to Interferon-Beta or Glatiramer Acetate in Patients With Multiple Sclerosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "Teriflunomide",
          "type": "DRUG"
        },
        {
          "name": "Placebo (for teriflunomide)",
          "type": "DRUG"
        },
        {
          "name": "Interferon-β [IFN-β]",
          "type": "DRUG"
        },
        {
          "name": "Glatiramer Acetate [GA]",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 182,
      "start_date": "2007-10",
      "completion_date": "2010-04",
      "has_results": true,
      "last_update_posted_date": "2012-12-31",
      "last_synced_at": "2026-10-15T03:45:43.835Z",
      "location_count": 1,
      "location_summary": "Bridgewater, New Jersey",
      "locations": [
        {
          "city": "Bridgewater",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00811395"
    },
    {
      "nct_id": "NCT01189812",
      "title": "Safety and Efficacy Study of Citalopram and Lithium for the Treatment of Depressive Mood Disorder Symptoms",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Major Depressive Disorder",
        "Dysthymia",
        "Depression Not Otherwise Specified",
        "Borderline Personality Disorder"
      ],
      "interventions": [
        {
          "name": "Lithium Carbonate",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Citalopram",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Columbia Northwest Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 80,
      "start_date": "2010-03",
      "completion_date": "2011-01",
      "has_results": true,
      "last_update_posted_date": "2011-08-24",
      "last_synced_at": "2026-10-15T03:45:43.835Z",
      "location_count": 2,
      "location_summary": "San Diego, California • Bellevue, Washington",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Bellevue",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01189812"
    },
    {
      "nct_id": "NCT02019875",
      "title": "CYP3A4 Activity and Mineral Homeostasis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Vitamin D and Calcium Homeostasis"
      ],
      "interventions": [
        {
          "name": "Rifampin",
          "type": "DRUG"
        },
        {
          "name": "Clarithromycin",
          "type": "DRUG"
        },
        {
          "name": "Grapefruit Juice",
          "type": "OTHER"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "University of Washington",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 92,
      "start_date": "2014-06",
      "completion_date": "2020-12",
      "has_results": true,
      "last_update_posted_date": "2023-04-19",
      "last_synced_at": "2026-10-15T03:45:43.835Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02019875"
    },
    {
      "nct_id": "NCT01781507",
      "title": "Study of Bronchodilation Effects of Cetirizine",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Allergic Rhinitis",
        "Asthma"
      ],
      "interventions": [
        {
          "name": "Cetirizine",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "California Allergy and Asthma Medical Group, Inc.",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 21,
      "start_date": "2011-06",
      "completion_date": "2011-12",
      "has_results": false,
      "last_update_posted_date": "2013-09-04",
      "last_synced_at": "2026-10-15T03:45:43.835Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01781507"
    }
  ]
}